Posttranscriptional regulation of T-cell IL-2 production by human pooled immunoglobin

Clinical Immunology and Immunopathology

Volumn 83, Issue 1, 1997, Pages 77-85

  Modiano, Jaime F ^a,b   Amran, David ^a   Lack, Gideon ^a   Bradley, Katherine ^a   Ball, Carrie ^b   Domenico, Joanne ^a   Gelfand, Erwin W ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INTERLEUKIN 2; LUCIFERASE; MONENSIN; STAUROSPORINE;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSCRIPTION REGULATION;

EID: 0031127018     PISSN: 00901229     EISSN: None     Source Type: Journal    
DOI: 10.1006/clin.1997.4329     Document Type: Article

References (52)

1. 1. Gelfand, E. W., Unique susceptibility to mycoplasma infection in patients with antibody deficiency. Clin. Infect. Dis. 17, 250-253, 1993.
2. 2. Boughton, B. J., Jackson, N., Lim, S., and Smith, N., Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia. Clin. Lab. Haematol. 17, 75-80, 1995.
3. 3. Haeney, M., Intravenous immune globulin in primary immunodeficiency. Clin. Exp. Immunol. 97(Suppl. 1), 11-15, 1994.
4. 4. Liese, J. G., Wintergerst, U., Tympner, K. D., and Belohradsky, B. H., High-vs low-dose immunoglobulin therapy in the long-term treatment of X-linked agammaglobulinemia. Am. J. Dis. Child. 146, 335-339, 1992.
5. 5. Crow, M. E., Intravenous immune globulin for prevention of bacterial infections in pediatric AIDS patients. Am. J. Health-Syst. Pharm. 52, 803-11, 1995.
6. 6. Gottlieb, F., and Deutsch, J., Red cell aplasia responsive to immunoglobulin therapy as initial manifestation of human immunodeficiency virus infection. Am. J. Med. 92, 331-333, 1992.
7. 7. Ettenger, R. B., and Yadin, O., The potential role of therapeutic antibodies in the regulation of rejection. Transplant. Proc. 27(5, Suppl. 1), 13-17, 1995.
8. 8. Glotz, D., Haymann, J. P., Sansonetti, N., Francois, A., Menoyo-Calonge, V., Bariety, J., and Druet, P., Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg): A potential tool for transplantation of immunized patients. Transplantation 56, 335-337, 1993.
9. 9. Fehr, J., Hofmann, V., and Kappeler, U., Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N. Engl. J. Med. 306, 1254-1258, 1982.
10. 10. Bussel, J. B., Kimberly, R. P., Inman, R. D., Schulman, I., Cunningham-Rundles, C., Cheung, N., Smithwick, E. M., O'Malley, J., Barandun, S., and Hilgartner, M. W., Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura. Blood 62, 480-486, 1983.
11. 11. Imbach, P., and Jungi, T. W., Possible mechanisms of intravenous immunoglobulin treatment in childhood idiopathic thrombocytopenic purpura (ITP). Blut 46, 117-124, 1983.
12. 12. Sultan, Y., Kazatchkine, M. D., Maisonneuve, P., and Nydegger, U. E., Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet 2, 765-768, 1984.
13. 13. Newburger, J. W., Takahashi, M., Burns, J. C., Beiser, A. S., Chung, K. J., Duffy, C. E., Glode, M. P., Mason, W. H., Reddy, V., Sanders, S. P., Shulman, S. T., Wiggins, J. W., Hicks, R. V., Fulton, D. R., Lewis, A. B., Leung, D. Y. M., Colton, T., Rosen, F. S., and Melish, M. E., The treatment of Kawasaki syndrome with intravenous gamma globulin. N. Engl. J. Med. 315, 341-347, 1986.
14. 14. Chipps, E., and C. Skinner, C., Intravenous immunoglobulin: Implications for use in the neurological patient. J. Neurosci. Nurs. 26, 8-17, 1994.
15. 15. Gelfand, E. W., Treatment of autoimmune diseases with intravenous gammaglobulin. Semin. Hematol. 29(3, Suppl. 2), 127-133, 1992.
16. 16. Kalden, J. R., Biologic agents in the therapy of inflammatory rheumatic diseases, including therapeutic antibodies, cytokines, and cytokine antagonists. Curr. Opin. Rheumatol. 6, 281-286, 1994.
17. 17. Kalden, J. R., and Manger, B., Biologic agents in the treatment of inflammatory rheumatic diseases. Curr. Opin. Rheumatol. 7, 191-197, 1995.
18. 18. Shoenfeld, Y., Immunosuppression of experimental systemic lupus erythematosus and antiphospholipid syndrome. Transplant. Proc. 26, 3211-3213, 1994.
19. 19. Tumiati, B., Casoli, P., Veneziani, M., and Rinaldi, G., High-dose immunoglobulin therapy as an immunomodulatory treatment of rheumatoid arthritis. Arthritis Rheumat. 35, 1126-1133, 1992.
20. 20. Sbrana, S., Ruocco, L., Vanacore, R., Azzara, A., and Ambrogi, F., In vitro effects of an immunoglobulin preparation for intravenous use (IVIG) on T-cells activation. Allerg. Immunol. 25, 35-37, 1993.
21. 21. Andersson, U., Bjork, L., Skansen-Saphir, U., and Andersson, J., Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol. Rev. 139, 21-42, 1994.
22. 22. Andersson, U. G., Bjork, L., Skansen-Saphir, U., and Andersson, J. P., Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG. Immunology 79, 211-216, 1993.
23. 23. Stohl, W., Cellular mechanisms in the in vitro inhibition of pokeweed mitogen-induced B cell differentiation by immunoglobulin for intravenous use. J. Immunol. 136, 4407-4413, 1986.
24. 24. van Schaik, I. N., Lundkvist, I., Vermeulen, M., and Brand, A., Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro. J. Clin. Immunol. 12, 325-334, 1992.
25. 25. Kawada, K., and Terasaki, P. I., Evidence for immunosuppression by high-dose gammaglobulin. Exp. Hematol. 15, 133-136, 1987.
26. 26. Amran, D., Renz, H., Lack, G., Bradley, K., and Gelfand, E. W., Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglobulin. Clin. Immunol. Immunopathol. 73, 180-186, 1994.
27. 27. Smith, K. A., Interleukin-2: Inception, impact, and implications. Science. 240, 1169-1176, 1988.
28. 28. Smith, K. A., Interleukin-2. Curr. Opin. Immunol. 4, 271-276, 1992.
29. 29. Taniguchi, T., and Minami, Y., The IL-2/IL-2 receptor system: A current overview. Cell 73, 5-8, 1993.
30. 30. Crabtree, G. R., and Clipstone, N. A., Signal transmission between the plasma membrane and nucleus of T lymphocytes. Annu. Rev. Biochem. 63, 1045-1083, 1994.
31. 31. Robb, R. J., Kutny, R. M., Panico, M., Morris, H. R., and Chowdhry, V., Amino-acid sequence and post-translational modifications of human interleukin 2. Proc. Natl. Acad. Sci. USA 81, 6486-6490, 1984.
32. 32. Modiano, J. F., Kolp, R., Lamb, R. J., and Nowell, P. C., Protein kinase C regulates both production and secretion of interleukin 2. J. Biol. Chem. 266, 10552-10561, 1991.
33. 33. Rooney, J. W., Sun, Y. L., Glimcher, L. H., and Hoey, T., Novel NFAT sites that mediate activation of the interleukin-2 promoter in response to T-cell receptor stimulation. Mol. Cel. Biol. 15, 6299-6310, 1995.
34. 34. Kung, H. F., Calvert, I., Bekesi, E., Kahn, F. R., Huang, K. P., Oroszlan, S., Henderson, L. E., Copeland, T. D., Sowder, R. C., and Wei, S. J., Phosphorylation of human interleukin-2 (IL-2). Mol. Cell. Biochem. 89, 29-35, 1989.
35. 35. Modiano, J. F., Domenico, J., Szepesi, A., Lucas, J. J., and Gelfand, E. W., Differential requirements for interleukin-2 distinguish the expression and activity of the cyclin-dependent kinases cdk4 and cdk2 in human T cells. J. Biol. Chem. 269, 32972-32978, 1994.
36. 36. Rabin, H., Hopkins, III, R. F., Ruscetti, F. W., Neubauer, R. H., Brown, R. L., and Kawakami, T. G., Spontaneous release of a factor with properties of a T cell growth factor from a continuous line of primate tumor cells. J. Immunol. 127, 1852-1856, 1981.
37. 37. Chen, S. J., Holbrook, N. J., Mitchell, K. F., Vallone, C. A., Greengard, J. S., Crabtree, G. R., and Lin, Y., A viral long terminal repeat in the interleukin 2 gene of a cell line that constitutively produces interleukin 2. Proc. Natl. Acad. Sci. USA 82, 7284-7288, 1985.
38. 38. Wilkinson, M., RNA isolation: A mini-prep method. Nucleic Acids Res. 16, 10933, 1988.
39. 39. Holbrook, N. J., Smith, K. A., Fornace, Jr., A. J., Comeau, C. M., Wiskocil, R. L., and Crabtree, G. R., T-cell growth factor: Complete nucleotide sequence and organization of the gene in normal and malignant cells. Proc. Natl. Acad. Sci. USA 81, 1634-1638, 1984.
40. 40. Suggs, S. V., Wallace, B. R., Hirose, T., Kawashima, E., and Itakura, K., Use of synthetic oligonucleotides as hybridization probes: Isolation of cloned cDNA sequences for beta-2-microglobulin. Proc. Natl. Acad. Sci. USA 78, 6613-6617, 1981.
41. 41. Terada, N., Lucas, J. J., Szepesi, A., Franklin, R. A., Domenico, J., and Gelfand, E. W., Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of the middle to late G1 phase of the cycle. J. Cell. Physiol. 154, 7-15, 1993.
42. 42. Durand, D. B., Bush, M. R., Morgan, J. G., Weiss, A., and Crabtree, G. R., A 275 basepair fragment at the 5′ end of the interleukin 2 gene enhances expression from a heterologous promoter in response to signals from the T cell antigen receptor. J. Exp. Med. 165, 395-407, 1987.
43. 43. Kloth, S., Flad, H. D., and Brandt, E., Detection of intracellular interleukin 2: Evidence for novel immunologically related forms of the lymphokine. Cytokine 6, 349-357, 1994.
44. 44. Cunningham-Rundles, C., Zhou, Z., Mankarious, S., and Courter, S., Long-term use of IgA-depleted intravenous immunoglobulin in immunodeficient subjects with anti-IgA antibodies. J. Clin. Immunol 13, 272-278, 1993.
45. 45. Nadal, D., Lauener, R. P., Braegger, C. P., Kaufhold, A., Simma, B., Lutticken, R., and Seger, R. A., T cell activation and cytokine release in streptococcal toxic shock-like syndrome. J. Pediat. 122, 727-729, 1993.
46. 46. Rigal, D., Vermot-Desroches, C., Heitz, S., Bernaud, J., Alfonsi, F., and Monier, J. C., Effects of intravenous immunoglobulins (IVIG) on peripheral blood B, NK, and T cell subpopulations in women with recurrent spontaneous abortions: Specific effects on LFA-1 and CD56 molecules. Clin. Immunol. Immunopathol. 71, 309-314, 1994.
47. 47. Or, R., Renz, H., Terada, N., and Gelfand, E. W., IL-4 and IL-2 promote human T-cell proliferation through symmetrical but independent pathways. Clin. Immunol. Immunopathol. 64, 210-217, 1992.
48. 48. Modiano, J. F., Domenico, J., Szepesi, A., Terada, N., Lucas, J. J., and Gelfand, E. W., Symmetry of the activation of cyclin-dependent kinases in mitogen and growth factor-stimulated T lymphocytes. Ann. N.Y. Acad. Sci. 766, 134-148, 1995.
49. 49. Gaulton, G. N., and Williamson, P., Interleukin-2 and the inter leukin-2 receptor complex. Chem. Immunol. 59, 91-114, 1994.
50. 50. Pignata, C., Prasad, K. V., Robertson, M. J., Levine, H., Rudd, C. E., and Ritz, J., Fc gamma RIIIa-mediated signaling involves src-family lck in human natural killer cells. J. Immunol. 151, 6794-6800, 1993.
51. 51. Van den Herik-Oudijk, I. E., Capel, P. J., van der Bruggen, T., and Van de Winkel, J. G., Identification of signaling motifs within human Fc gamma RIIa and Fc gamma RIIb isoforms. Blood 85, 2202-2211, 1995.
52. 52. Van den Herik-Oudijk, I. E., Ter Bekke, M. W., Tempelman, M. J., Capel, P. J., and Van de Winkel, J. G., Functional differences between two Fc receptor ITAM signaling motifs. Blood 86, 3302-3307, 1995.